Ryo Koyama-Nasu Motoko Y. Kimura Masahiro Kiuchi Ami Aoki Yangsong Wang Yukiyoshi Mita Ichita Hasegawa Yukihiro Endo Atsushi Onodera Kiyoshi Hirahara Shinichiro Motohashi Toshinori Nakayama
Cancer Immunology Research 11(8) 1085-1099 2023年5月 [査読有り]
Abstract
Tumor-specific CD8+ T cells play a pivotal role in antitumor immunity and are a key target of immunotherapeutic approaches. Intratumoral CD8+ T cells are heterogeneous; Tcf1+ stemlike CD8+ T cells give rise to their cytotoxic progeny—Ti...
Ryo Koyama-Nasu Yangsong Wang Ichita Hasegawa Yukihiro Endo Toshinori Nakayama Motoko Y Kimura
International Immunology 34(11) 555-561 2022年6月 [招待有り]
Abstract
Cancer immunotherapy utilizes our immune system to attack cancer cells and is an extremely promising strategy for cancer treatment. Although immune-checkpoint blockade, such as anti-PD-1 (programmed cell death 1) antibody, has demonstrat...
Murshed H. Sarkar Ryoji Yagi Yukihiro Endo Ryo Koyama-Nasu Yangsong Wang Ichita Hasegawa Toshihiro Ito Ilkka S. Junttila Jinfang Zhu Motoko Y. Kimura Toshinori Nakayama
PLOS ONE 16(11) e0260204-e0260204 2021年11月 [査読有り]
While IFNγ is a well-known cytokine that actively promotes the type I immune response, it is also known to suppress the type II response by inhibiting the differentiation and proliferation of Th2 cells. However, the mechanism by which IFNγ suppres...
Cancer Immunology, Immunotherapy 70(5) 1239-1254 2020年10月 [査読有り]
Abstract
Glioblastoma is the most common and aggressive type of brain tumor with high recurrence and fatality rates. Although various therapeutic strategies have been explored, there is currently no effective treatment for glioblastoma. Recently,...
大学院国際学術研究院